Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Haas, Sylvia ^a   Schellong, Sebastian M ^b   Tebbe, Ulrich ^c   Gerlach, Horst Eberhard ^d   Bauersachs, Rupert ^e   Melzer, Nima ^f   Abletshauser, Claudia ^f   Sieder, Christian ^f   Bramlage, Peter ^g   Riess, Hanno ^h  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^c KLINIKUM LIPPE DETMOLD   (Germany)

^d University Medical Centre   (Germany)

^e KLINIKUM DARMSTADT   (Germany)

^f NOVARTIS PHARMA GMBH   (Germany)

^g Institute for Cardiovascular Pharmacology and Epidemiology   (Germany)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; MONOEMBOLEX; ANTICOAGULANT AGENT; CERTOPARIN; DRUG DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN;

AGED; ARTICLE; BLEEDING; CANCER PATIENT; CAUSE OF DEATH; COMORBIDITY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMBOLISM PREVENTION; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; VENOUS THROMBOEMBOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MULTICENTER STUDY; NEOPLASM; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; STATISTICS; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LOGISTIC MODELS; MALE; NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 79960657749     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-316     Document Type: Article

References (26)

1. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000, 160(6):809-815. 10.1001/archinte.160.6.809, 10737280.
2. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006, 4(3):529-535. 10.1111/j.1538-7836.2006.01804.x, 16460435.
3. Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002, 162(11):1245-1248. 10.1001/archinte.162.11.1245, 12038942.
4. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000, 343(25):1846-1850. 10.1056/NEJM200012213432504, 11117976.
5. Alcalay A, Wun T, Khatri V, Chew HK, Harvey D, Zhou H, White RH. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 2006, 24(7):1112-1118. 10.1200/JCO.2005.04.2150, 16505431.
6. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006, 166(4):458-464. 10.1001/.458, 16505267.
7. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002, 100(10):3484-3488. 10.1182/blood-2002-01-0108, 12393647.
8. Krauth D, Holden A, Knapic N, Liepman M, Ansell J. Safety and efficacy of long-term oral anticoagulation in cancer patients. Cancer 1987, 59(5):983-985. 10.1002/1097-0142(19870301)59:5<983::AID-CNCR2820590522>3.0.CO;2-O, 3815277.
9. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000, 18(17):3078-3083.
10. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6 Suppl):381S-453S. 10.1378/chest.08-0656, 18574271.
11. AWMF 2010. [S3-Guideline: Prophylaxis of venous thromboembolism (VTE)]. , http://www.awmf.org/leitlinien/detail/ll/003-001.html
12. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007, 25(34):5490-5505. 10.1200/JCO.2007.14.1283, 17968019.
13. Wagman LD, Baird MF, Bennett CL, Bockenstedt PL, Cataland SR, Fanikos J, Fogarty PF, Goldhaber SZ, Grover TS, Haire W, Hassoun H, Jahanzeb M, Leung LL, Linenberger ML, Millenson MM, Ortel TL, Salem R, Smith JL, Streiff MB. Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006, 4(9):838-869.
14. Mandala M, Falanga A, Roila F. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management. Ann Oncol 2010, 21(Suppl 5):v274-276.
15. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999, 341(11):793-800. 10.1056/NEJM199909093411103, 10477777.
16. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004, 110(7):874-879. 10.1161/01.CIR.0000138928.83266.24, 15289368.
17. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006, 332(7537):325-329. 10.1136/bmj.38733.466748.7C, 1363908, 16439370.
18. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson CG, Turpie AG. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004, 164(9):963-968. 10.1001/archinte.164.9.963, 15136304.
19. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004, 22(10):1944-1948. 10.1200/JCO.2004.10.002, 15143088.
20. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, Buller HR. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005, 23(10):2130-2135. 10.1200/JCO.2005.03.134, 15699479.
21. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004, 2(8):1266-1271. 10.1111/j.1538-7836.2004.00871.x, 15304029.
22. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R, Alberts SR, Morton RF, Rowland KM, Novotny PJ, Loprinzi CL. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006, 81(6):758-767. 10.4065/81.6.758, 16770976.
23. Lazo-Langner A, Goss GD, Spaans JN, Rodger MA. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007, 5(4):729-737. 10.1111/j.1538-7836.2007.02427.x, 17408406.
24. Riess H, Haas S, Tebbe U, Gerlach H-E, Abletshauser C, Sieder C, Bramlage P, Schellong S. A randomized, double-blind, multicenter study of certoparin versus UFH to prevent venous thromboembolic events in acutely ill, non-surgical patients; The CERTIFY Study. J Thromb Haemost 2010, 8(6):1209-1215. 10.1111/j.1538-7836.2010.03848.x, 20218984.
25. Tebbe U, Schellong SM, Haas S, Gerlach HE, Abletshauser C, Sieder C, Bramlage P, Riess H. Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: A subgroup analysis of the randomized, controlled CERTIFY study. Am Heart J 2011, 161(2):322-328. 10.1016/j.ahj.2010.10.005, 21315215.
26. Rousson V, Seifert B. A mixed approach for proving non-inferiority in clinical trials with binary endpoints. Biom J 2008, 50(2):190-204. 10.1002/bimj.200710410, 18311852.